Daniel Keri,Matt Walker,Isha Singh et al.
Daniel Keri et al.
Multispecific antibodies recognize two or more epitopes located on the same or distinct targets. This added capability through protein design allows these man-made molecules to address unmet medical needs that are no longer possible with si...
CD80-Fc fusion protein as a potential cancer immunotherapy strategy [0.03%]
CD80-Fc融合蛋白作为一种潜在的癌症免疫治疗策略
Songna Wang,Pinliang Hu,Jiajun Fan et al.
Songna Wang et al.
The activation of T lymphocytes is a crucial component of the immune response, and the presence of CD80, a membrane antigen, is necessary for T-cell activation. CD80 is usually expressed on antigen-presenting cells (APCs), which can interac...
A disruptive clickable antibody design for the generation of antibody-drug conjugates [0.03%]
一种用于抗体药物偶联物生成的干扰性可点击型抗体设计法
Nathanaël Rakotoarinoro,Yan F K Dyck,Simon K Krebs et al.
Nathanaël Rakotoarinoro et al.
Background: Antibody-drug conjugates are cancer therapeutics that combine specificity and toxicity. A highly cytotoxic drug is covalently attached to an antibody that directs it to cancer cells. The conjugation of the dru...
Mapping the protein-protein interactome in the tumor immune microenvironment [0.03%]
绘制肿瘤免疫微环境中蛋白质相互作用图谱
Rui Peng,Mi Deng
Rui Peng
The cell-to-cell communication primarily occurs through cell-surface and secreted proteins, which form a sophisticated network that coordinates systemic immune function. Uncovering these protein-protein interactions (PPIs) is indispensable ...
Development of a human glioblastoma model using humanized DRAG mice for immunotherapy [0.03%]
人源化DRAG小鼠脑胶质瘤模型的建立及其免疫治疗效应研究
Rashmi Srivastava,Alireza Labani-Motlagh,Apeng Chen et al.
Rashmi Srivastava et al.
Glioblastoma (GBM) is the most common and lethal primary brain tumor. The development of alternative humanized mouse models with fully functional human immune cells will potentially accelerate the progress of GBM immunotherapy. We successfu...
Effects of arginine in therapeutic protein formulations: a decade review and perspectives [0.03%]
精氨酸在蛋白药物制剂中的作用：十年回顾及展望
Steven Ren
Steven Ren
Arginine (Arg) is a natural amino acid with an acceptable safety profile and a unique chemical structure. Arg and its salts are highly effective in enhancing protein refolding and solubilization, suppressing protein-protein interaction and ...
In vitro generated antibodies guide thermostable ADDomer nanoparticle design for nasal vaccination and passive immunization against SARS-CoV-2 [0.03%]
体外生成的抗体引导设计稳定的ADDomer纳米颗粒以用于新型冠状病毒鼻腔疫苗及被动免疫疗法
Dora Buzas,Adrian H Bunzel,Oskar Staufer et al.
Dora Buzas et al.
Background: Due to COVID-19, pandemic preparedness emerges as a key imperative, necessitating new approaches to accelerate development of reagents against infectious pathogens. ...
Bringing cell therapy to tumors: considerations for optimal CAR binder design [0.03%]
使细胞疗法作用于肿瘤：关于最佳CAR结合器设计的考量因素
Richard Smith
Richard Smith
Chimeric antigen receptor (CAR)-T cells have revolutionized the immunotherapy of B-cell malignancies and are poised to expand the range of their impact across a broad range of oncology and non-oncology indications. Critical to the success o...
IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy [0.03%]
人源化单克隆抗体IMM47通过靶向CD24抑制CD24与Siglec-10相互作用可单独使用或与抗PD1抗体联合用于癌症免疫治疗并表现出优异的抗肿瘤效果
Song Li,Dianze Chen,Huiqin Guo et al.
Song Li et al.
This study evaluates the anti-tumor mechanism of IMM47, a humanized anti-CD24 mAb. Biolayer interferometry, ELISA and flow cytometry methods were used to measure the IMM47 binding, affinity, ADCC, ADCP, ADCT and CDC activities. In vivo ther...
Comparability strategy and demonstration for post-approval production cell line change of a bevacizumab biosimilar IBI305 [0.03%]
贝伐珠单抗类似药IBI305上市后生产细胞系变更的可比性研究及验证
Zhouyi Wu,Gangling Xu,Wu He et al.
Zhouyi Wu et al.
High-producing cell line could improve the affordability and availability of biotherapeutic products. A post-approval production cell line change, low-titer CHO-K1S to high-titer CHO-K1SV GS-KO, was performed for a China marketed bevacizuma...